CAR-T Overview









Overview

What is a CAR-T therapy?
The chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for a variety of cancers. The idea is to take out the T-cells from the patient, and genetically engineer the cells to make them express a chimeric antigen receptor (CAR) recognizing a specific tumor-associated antigen (TAAs). As a result, the CAR-expressing T cells, when reintroduced into the patient's body, will target and eliminate the TAA-expressing tumor cells.
What patients are benefitting from CAR-T?
The CAR-T clinical trial in Lu Daopei Hospital is for patients with B-cell acute lymphocytic leukemia(B-ALL), B-cell lymphoma and multiple myeloma, who developed refractory or relapsed disease from chemotherapy.
What is the benefit of receiving bone marrow transplantation (BMT) after CAR-T therapy?
Although the complete remission (CR) rate of CAR-T treatment is high, the risk of relapse still present. Studies have been show that bridging BMT after CAR-T for B-ALL could further increase the potential cure rate.

Please click here to learn more information about CAR-T therapy.
If you want to know more about CAR-T Clinical Trial please go to CAR-T Clinical Trial 
Recruitment.









Stay in Touch
©2017 Lu Daopei hospital-22 Tongji South Rd, Yizhuang Ecomonic and Technological Development Zone, Daxing District, Beijing, China. All rights reserved.
冀ICP备18002416号-1